Celularity (CELU) EBITDA Margin (2020 - 2025)
Celularity (CELU) posted quarterly EBITDA Margin of 537.48% for Q4 2025, up 81136.0% year-over-year from N/an in Q4 2024, and down 120.16% quarter-over-quarter from 244.13% in Q3 2025.
Celularity (CELU) EBITDA Margin (2020 - 2025) Analysis & Trends
Celularity (CELU) has reported EBITDA Margin for 6 consecutive years, with 537.48% the latest figure, recorded in Q4 2025.
- In Q4 2025, EBITDA Margin rose 81136.0% year-over-year to 537.48%; the TTM figure through Dec 2025 stood at 230.92% (down 12661.0% YoY), while the FY2025 annual figure was 230.92%, down 16017.0% from the prior year.
- EBITDA Margin retreated to 537.48% in Q4 2025 per CELU's latest filing, from 244.13% in the prior quarter.
- Across five years, EBITDA Margin topped out at 423.47% in Q4 2022 and bottomed at 2621.66% in Q3 2023.
- Historically, EBITDA Margin has averaged 620.57% across 5 years, with a median of 260.35% in 2025.
- Annual changes were most pronounced in 2023 — EBITDA Margin tumbled 248512 bps — and 2024, when it soared 249766 bps.
- Celularity's EBITDA Margin stood at 307.89% in 2021, then jumped by 238 bps to 423.47% in 2022, then tumbled by 74 bps to 109.93% in 2023, then tumbled by 1327 bps to 1348.84% in 2024, then surged by 60 bps to 537.48% in 2025.
- Business Quant data shows CELU's EBITDA Margin at 537.48% in Q4 2025, 244.13% in Q3 2025, and 276.57% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 19.75% |
| 10 | Celularity | 21.76 Mn | 15.58 Mn | -3.27 Mn | -537.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -537.48% |
| Sep 30, 2025 | -244.13% |
| Jun 30, 2025 | -276.57% |
| Mar 31, 2025 | -91.77% |
| Dec 31, 2024 | -1,348.84% |
| Sep 30, 2024 | -124.00% |
| Jun 30, 2024 | -84.01% |
| Mar 31, 2024 | -50.24% |
| Dec 31, 2023 | 109.93% |
| Sep 30, 2023 | -2,621.66% |
| Jun 30, 2023 | -1,445.75% |
| Mar 31, 2023 | -1,623.13% |
| Dec 31, 2022 | 423.47% |
| Sep 30, 2022 | -136.54% |
| Jun 30, 2022 | 110.57% |
| Mar 31, 2022 | -701.16% |
| Dec 31, 2021 | -307.89% |
| Sep 30, 2021 | 102.60% |
| Jun 30, 2021 | -1,895.87% |
| Mar 31, 2021 | -1,668.98% |